The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Effects of epidermal growth factor receptor inhibitor‐induced dermatologic toxicities on quality of life
Open accessAbstract
BACKGROUND: Epidermal growth factor receptor (EGFR) inhibitors frequently result in dermatologic toxicities, including rash, xerosis, pruritus, and paronychia. Although the frequency and severity of these events have been described, their effect on health‐related quality of life (QoL) remains poorly understood. By using a dermatology‐specific questionnaire, the authors examined the effect of these toxicities on QoL. METHODS: Patients completed the Skindex‐16, a questionnaire that measures the effects on 3 domains of QoL: symptoms, emotions, and functioning. The severity of dermatologic toxicities was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0 (NCI‐CTCAE). Correlations of dermatology QoL scores with NCI‐CTCAE grade, skin phototype (SPT), sex, age, type of EGFR inhibitor, and cancer type were investigated. RESULTS: Concordant with greater severity of rash grade, there was an increase in median scores for symptoms (P = .0006), emotions (P < .0001), function (P = .001), and overall score (P < .0001). There was an inverse correlation between age and emotions (r = −0.26; P = .03) and overall score (r = −0.25; P = .04). There was a significant difference between patients aged ≤50 years and patients aged >50 years with regard to symptoms (P = .02), emotions (P = .03), functioning (P = .04), and overall score (P = .02). There were no significant differences between QoL and SPT, sex, treatment type, or cancer type (P > .05). CONCLUSIONS: Toxicities, including rash, xerosis, paronychia, and pruritus, adversely affected QoL, and rash was associated with a QoL greater decrease. Younger patients reported lower overall QoL than older patients who had the same toxicities. The current results support using the NCI‐CTCAE as a correlative tool for measuring the effects of rash on dermatology‐specific QoL. Cancer 2010. © 2010 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Velikova, G., Booth, L., Smith, A. B., Brown, P. M., Lynch, P., Brown, J. M., & Selby, P. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.078 · Cited by 1,382
Basch, E., Iasonos, A., McDonough, T., Barz, A., Culkin, A., Kris, M. G., Scher, H. I., & Schrag, D. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70910-x · Cited by 653
Quality of Life Among Younger Women With Breast Cancer
Avis, N. E., Crawford, S., & Manuel, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.130 · Cited by 529
Cited by
Chen, A. P., Setser, A., Anadkat, M. J., Cotliar, J., Olsen, E. A., Garden, B. C., & Lacouture, M. E. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.02.010 · Cited by 350
Self-citationUnderstanding, recognizing, and managing toxicities of targeted anticancer therapies
Dy, G. K., & Adjei, A. A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21184 · Cited by 331
Hofheinz, R.-D., Deplanque, G., Komatsu, Y., Kobayashi, Y., Ocvirk, J., Racca, P., Guenther, S., Zhang, J., Lacouture, M. E., & Jatoi, A. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0051 · Cited by 88
Self-citation
Metadata
- Authors
- Joshi, S. S., Ortiz, S., Witherspoon, J. N., Rademaker, A., West, D. P., Anderson, R., Rosenbaum, S. E., & Lacouture, M. E.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2010-08-04
- Volume
- 116
- Issue
- 16
- Pages
- 3916-3923
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2073205257
- Cited by
- 170
- References
- 3
- FWCI
- 15.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of epidermal growth factor receptor inhibitor‐induced dermatologic toxicities on quality of life. https://app.cochat.ai/papers/10.1002/cncr.25090
- The paper
- Joshi, S. S., Ortiz, S., Witherspoon, J. N., Rademaker, A., West, D. P., Anderson, R., Rosenbaum, S. E., & Lacouture, M. E. (2010). Effects of epidermal growth factor receptor inhibitor‐induced dermatologic toxicities on quality of life. Cancer. https://doi.org/10.1002/cncr.25090
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.